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OBJECTIVES The objective of this study was to characterize temporal changes in defibrillation thresholds
(DFTs) after implantation with an active pectoral, dual-coil transvenous lead system.
BACKGROUND Ventricular DFTs rise over time when monophasic waveforms are used with non-
thoracotomy lead systems. This effect is attenuated when biphasic waveforms are used with
transvenous lead systems; however, significant increases in DFT still occur in a minority of
patients. The long-term stability of DFTs with contemporary active pectoral lead systems is
unknown.
METHODS This study was a prospective assessment of temporal changes in DFT using a uniform testing
algorithm, shock polarity and dual-coil active pectoral lead system. Thresholds were measured
at implantation, before discharge and at long-term follow-up (70 6 40 weeks) in 50 patients.
RESULTS The DFTs were 9.2 6 5.4 J at implantation, 8.3 6 5.8 J before discharge and 6.9 6 3.6 J at
long-term follow-up (p , 0.01 by analysis of variance; p , 0.05 for long-term follow-up vs.
at implantation or before discharge). The effect was most marked in a prespecified subgroup
with high implant DFTs ($15 J). No patient developed an inadequate safety margin (,9 J)
during follow-up.
CONCLUSIONS The DFTs declined significantly after implantation with an active pectoral, dual-coil
transvenous lead system, and no clinically significant increases in DFT were observed.
Therefore, routine defibrillation testing may not be required during the first two years after
implantation with this lead system, in the absence of a change in the cardiac substrate or
treatment with antiarrhythmic drugs. (J Am Coll Cardiol 2001;38:1150–5) © 2001 by the
American College of Cardiology
Implantable cardioverter-defibrillators (ICDs) decrease
mortality among patients who present with sustained ven-
tricular arrhythmias (1) and those with ischemic cardiomy-
opathy who have inducible, sustained ventricular arrhyth-
mias during electrophysiologic studies (2,3). It is likely that
the expected survival of patients with an ICD will continue
to improve as effective new treatments for congestive heart
failure are incorporated into clinical practice (4,5). The
improved survival of patients with an ICD and the expand-
ing indications for ICD placement have contributed to a
dramatic increase in the number of patients who require
longitudinal follow-up for their devices. Although the
efficacy of the ICD for terminating ventricular arrhythmias
is well established, it is contingent on the presence of an
adequate safety margin for defibrillation and the integrity of
the pulse generator and lead system. Certain malfunctions,
such as lead dislodgment, fracture, insulation defects or
random failure of pulse generator components can be
discovered during routine ICD interrogation, including
measurement of lead impedance and pacing and sensing
thresholds (6,7). However, some patients may develop an
inadequate safety margin for defibrillation over time, which
would not be recognized without defibrillation testing. Such
late increases in defibrillation thresholds (DFTs) have been
reported with several transvenous and hybrid lead systems
(8–15). Although many different lead systems were previ-
ously used for ventricular defibrillation, the most common
configuration now consists of an active pectoral can with a
transvenous lead, because of the simplicity of the implanta-
tion procedure and enhanced treatment efficacy (16–18). In
the present study, we report the first long-term follow-up of
temporal changes in DFT with a dual-coil, active pectoral
lead system.
METHODS
Patient group. The inclusion criterion for this prospective
study was initial pectoral ICD placement for standard
clinical indications. The indications for ICD placement
were sustained monomorphic ventricular tachycardia or
ventricular fibrillation arrest (48%), syncope with inducible,
sustained ventricular tachycardia at electrophysiologic test-
ing (30%) and ischemic cardiomyopathy with asymptom-
atic, nonsustained ventricular tachycardia and inducible,
sustained ventricular tachycardia at electrophysiologic test-
ing (22%). Exclusion criteria were a medical condition that
precluded ICD testing, inability to return for follow-up
testing, implantation of a subcutaneous array or patch,
unwillingness or inability to give informed consent or
participation in another research protocol.
The null hypothesis was that long-term DFTs would be
unchanged, compared with DFTs at implantation. The
sample size of 50 patients was chosen to provide .90%
power to detect a 25% change in DFT, which would be
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clinically relevant. Enrollment commenced in May 1996
and concluded in February 1999. The clinical characteristics
of the 50 study patients were compared with those of all
other eligible patients (n 5 181) who underwent initial
pectoral ICD placement with an active pectoral, dual-coil
transvenous lead system at our institution during this
interval. Informed, written consent was obtained from each
patient, and this study was approved by the Institutional
Review Board at the University of Maryland.
Defibrillator implantation. A uniform lead system and
biphasic waveform were used in this study to eliminate any
confounding influence of these factors on the results. All
defibrillator components used in this study were manufac-
tured by Cardiac Pacemakers Inc. (Guidant Corp., St. Paul,
Minnesota). The transvenous passive-fixation defibrillation
lead (Endotak DSP, models 0125 and 0145, Guidant
Corp.) was placed under fluoroscopic guidance at the right
ventricular apex through a subclavian, cephalic or axillary
vein. This is a tripolar lead consisting of a distal electrode
for sensing and pacing, a distal platinum coil (450 mm2) in
the right ventricle and a proximal platinum coil (660 mm2)
at the right atrium–superior vena cava junction. The dis-
tance from the lead tip to the proximal coil is 18 cm. The
active can was either a defibrillator emulator (model 6967)
or a pulse generator, which was placed subcutaneously in the
left (n 5 45) or right (n 5 5) prepectoral space. The pulse
generators used in the study included the Mini (models
1640, 1742 and 1743, Guidant Corp.) in 9 patients, Mini II
(models 1762 and 1763, Guidant Corp.) in 31 patients,
Mini III or IV (models 1782 and 1790, Guidant Corp.) in
6 patients and AV or AVII (models 1810 and 1821,
Guidant Corp.) in 4 patients.
Defibrillation threshold testing. According to the study
protocol, in each patient, DFTs were measured at implan-
tation, before discharge (1 to 3 days after implantation) and
at least six months after implantation. Although the mini-
mal required length of follow-up was six months, long-term
DFT testing was performed at later intervals whenever
possible. Long-term DFT testing was done electively on an
outpatient basis in the majority of patients (80%); the
remaining patients (20%) underwent long-term DFT test-
ing before initiation of antiarrhythmic drugs, when they
presented with frequent ICD discharges due to atrial or
ventricular arrhythmias. All testing was performed using
conscious sedation with midazolam and fentanyl.
Ventricular fibrillation was induced with T-wave shocks
or high-output ramp pacing through the defibrillation lead.
The distal coil was the cathode, and the proximal coil and
active can were connected electrically as the anode (i.e.,
normal polarity) for the first phase of the biphasic shock in
all patients (19). At implantation, an emulator was used as
the active pectoral electrode, and testing was performed
with an external defibrillator (ECD, model 2815, Guidant
Corp.), whereas at follow-up evaluations, device-based test-
ing was performed with the pulse generator shell as the
active pectoral electrode. Impedance measurements were
made from pulse generator discharges of comparable ener-
gies at implantation and follow-up (20). The ECD, Mini
and AV pulse generators have a capacitance of 140 mF,
whereas the Mini II and AVII pulse generators have a
capacitance of 125 mF. Mini III and IV have a capacitance
of 105 mF. The biphasic waveform tilt is the same for all of
these devices (60% first-phase tilt, 50% second-phase tilt).
A standard step-down DFT testing protocol was em-
ployed. The initial delivered shock energy for testing was
15 J. If successful, the energy was decreased to 10, 8, 5, 3
and 1 J on successive trials until defibrillation failed. If the
initial 15-J shock failed, the energy was increased in 5-J
steps on subsequent trials until defibrillation was successful.
The DFT was defined as the lowest initial shock energy that
successfully terminated ventricular fibrillation. The same
protocol was used at follow-up, regardless of preceding
measurements of DFT.
An adequate safety margin was defined as two or more
consecutive successful shocks with delivered energies at least
9 J below the maximal output of the pulse generator. The
maximal delivered outputs of the pulse generators employed
in this study were 29 J (models 1640, 1742, 1743 and 1810;
n 5 11) and 27 J (models 1762, 1763, 1782, 1790 and 1821;
n 5 39). The first six available delivered shock energy
settings for these devices are 29, 27, 25, 20, 18 and 15 J. The
9-J safety margin was chosen as the closest approximation of
the arbitrary clinical standard of $10 J (20 J for 29-J devices,
18 J for 27-J devices), which has been associated with a very
low incidence of sudden death (21). To ensure an adequate
safety margin, a confirmatory defibrillation trial was per-
formed in those patients with high DFTs ($15 J). The
results of the confirmatory trial were not used for statistical
analysis.
Data analysis. Group changes in DFTs were analyzed for
the entire cohort, as well as for a prospectively defined
subgroup of patients with high thresholds ($15 J) at
implantation. This subgroup was chosen because a rise in
thresholds in these patients is most likely to result in an
inadequate safety margin. Analysis was also performed on
subjects who demonstrated any increase in DFT ($1 J) at
follow-up. Standard clinical variables of age, gender, ejec-
tion fraction, etiology of heart disease and clinical conges-
tive heart failure, as well as the measured variables of DFT
and shock impedance, were compared between patients
with and those without a temporal rise in DFT. One-way
repeated measures analysis of variance (ANOVA) was used
to assess temporal changes in DFT and shock impedance.
Comparisons at different evaluation times were performed
with paired t tests. To examine the hypothesis that the
Abbreviations and Acronyms
ANOVA 5 analysis of variance
DFT 5 defibrillation threshold
ICD 5 implantable cardioverter-defibrillator
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duration of follow-up affects temporal changes in DFT,
least-squares linear regression analysis was performed using
time as the dependent variable. All results are expressed as
the mean value 6 SD, and p # 0.05 was considered
significant.
RESULTS
Patient group. The mean age of this cohort of 50 patients
was 62 6 11 years. Women constituted 22% of the group.
Significant coronary artery disease was present in 70% of the
subjects, and 66% had a history of symptomatic congestive
heart failure (New York Heart Association functional class
II or III). Their mean ejection fraction was 34 6 12%.
Seven patients were treated with amiodarone at the time of
ICD placement. In four patients, amiodarone was discon-
tinued at the time of ICD placement. One patient was
treated with sotalol at the time of ICD placement and at
long-term follow-up. Importantly, the clinical characteris-
tics of the 50 study patients were not significantly different
from those of the other 181 patients who underwent initial
pectoral ICD placement with an active pectoral, dual-coil
transvenous lead system at our institution during this
interval (Table 1). All of the patients completed the study,
and there were no deaths or other complications related to
the DFT testing protocol.
Defibrillation threshold testing. The long-term DFT was
assessed at 70 6 40 weeks after ICD placement. No occult
malfunctions of the shocking lead were discovered during
the long-term DFT evaluation. The results of DFT testing
are shown in Table 2 and Figure 1. The mean DFT was
9.2 6 5.4 J at implantation, 8.3 6 5.8 J at hospital discharge
and 6.9 6 3.6 J at long-term follow-up (p , 0.01 by
ANOVA). The long-term DFT was significantly lower
than that at implantation and before discharge (p , 0.01 for
long-term follow-up vs. at implantation; p 5 0.04 for
long-term follow-up vs. before discharge). There were no
significant differences between the implantation and pre-
discharge DFTs in the entire study group or in any of the
prespecified subgroups. The capacitance of the ICD did not
influence temporal changes in DFT. Compared with the
DFT at implantation, the long-term DFT was unchanged
in 20 patients (40%), decreased in 25 patients (50%) and
increased in only 5 patients (10%). The average safety
margin at implantation was 18.2 6 5.3 J, and no patient
developed an inadequate safety margin (,9 J) during
follow-up. One patient had a DFT at implantation of 25 J
in normal polarity; however, this value was acceptable in
reverse polarity (15 J). This patient had a long-term
follow-up DFT of 15 J in normal polarity.
Only one of the five patients who had an increase in the
long-term DFT was treated with amiodarone. In the
subgroup that had an increase in the long-term DFT, the
mean long-term DFT was 7.8 J and the highest long-term
DFT was 10 J. All five of these patients had low DFTs
(,15 J) at implantation. The largest observed increase in
DFT was 5 J (n 5 1). The five patients who had an increase
in the long-term DFT did not differ from the rest of the
group with respect to age, gender, ejection fraction, DFT at
implantation or shock impedance.
Because withdrawal of amiodarone and treatment with
sotalol would both be expected to contribute to a temporal
decline in DFT (22), separate analyses were conducted after
excluding all patients who were treated with antiarrhythmic
drugs at the time of ICD placement. In this subgroup of 42
patients, the mean DFT was 9.0 6 5.2 J at implantation,
7.9 6 4.8 J before discharge and 6.8 6 3.2 J at long-term
follow-up (p , 0.05 by ANOVA; p , 0.01 for long-term
Table 1. Clinical Characteristics of the Study Group
Study Patients
(n 5 50)
Other Patients
With an ICD
(n 5 181)
Age (years) 62 6 11 63 6 12
Female 11 (22%) 32 (18%)
Coronary artery disease 35 (70%) 127 (70%)
Congestive heart failure 33 (66%) 118 (65%)
Ejection fraction (%) 34 6 12 31 6 14
Antiarrhythmic drugs*
Amiodarone 7 28
Sotalol 1 3
Other 0 4
Total 8 (16%) 35 (19%)
*Treatment at time of implantable cardioverter-defibrillator (ICD) placement. Data
are presented as the mean value 6 SD or number (%) of patients.
Table 2. Temporal Changes in the DFT
n
At
Implantation
Before
Discharge
Long-Term
Follow-Up
Total study group 50 9.2 6 5.4 8.3 6 5.8 6.9 6 3.6*†
DFT ,15 J 39 6.7 6 2.1 6.6 6 3.7 5.8 6 2.2‡
DFT $15 J 11 18.2 6 3.4 15.2 6 7.2 11.6 6 4.7*
*p , 0.01 vs. at implantation; †p 5 0.04 vs. before discharge; ‡p 5 0.02 vs. at
implantation. Data are presented as the mean value 6 SD.
DFT 5 defibrillation threshold.
Figure 1. A comparison of defibrillation thresholds (DFTs) at implanta-
tion and at long-term follow-up (.6 months) for the entire study group.
The DFTs decreased significantly at long-term follow-up compared with
at implantation (p , 0.01). The mean values 6 SD are presented.
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follow-up vs. at implantation; p 5 0.05 for long-term
follow-up vs. before discharge). The patients who were
treated with antiarrhythmic drugs at implantation were also
examined separately (n 5 8). The mean DFT in this
subgroup was 10.3 6 6.4 J at implantation, 10.6 6 9.1 J
before discharge and 7.4 6 5.4 J at long-term follow-up
(p 5 0.34).
There were small but significant changes in shock im-
pedance over time (p , 0.05 by ANOVA). The shock
impedance was similar at implantation and at long-term
follow-up (42.2 6 6.2 and 42.4 6 4.8 ohms, respectively,
p 5 NS). The shock impedance before discharge was
significantly lower than that at implantation and long-term
follow-up (39.6 6 5.4 ohms, p , 0.01 for both compari-
sons). Because shock impedance is measured differently by
the external defibrillator and the pulse generator, the most
relevant comparison is between the long-term and pre-
discharge impedances, which are both measured with the
pulse generator in a closed pocket. The increase in long-
term shock impedance (compared with that before dis-
charge) is consistent with our previous observations with
this lead (23).
Patients with high DFTs (>15 J) at implantation.
Eleven patients with high DFTs at implantation were
identified (22% of the study group). There were no distin-
guishing clinical characteristics of this subgroup. The DFTs
in this cohort were 18.2 6 3.4 J at implantation and 11.6 6
4.7 J at long-term follow-up (38% decrease, p , 0.001).
The average decline in DFT was significantly greater among
patients with high DFTs at implantation (6.5 6 4.5 J), as
compared with that in the rest of the study group (0.9 6
2.4 J, p 5 0.002). Two patients in the high DFT subgroup
had no change in the long-term DFT; the other nine
patients had a decrease in the long-term DFT, compared
with that at implantation. In addition, no patient had an
inadequate safety margin (,9 J) at the long-term evalua-
tion. Only one patient in the high DFT subgroup was
treated with antiarrhythmic drugs (amiodarone) at the time
of implantation; the drug was discontinued when the DFT
at implantation was 20 J. This patient did not have any
change in DFT at long-term follow-up.
Effect of duration of follow-up on temporal changes in
DFT. Although long-term DFT testing was performed at
least six months after ICD placement in all patients, there
was significant variability in the duration of follow-up.
Importantly, there was no correlation between the duration
of follow-up and temporal changes in DFT (R2 5 0.001,
p 5 0.79) (Fig. 2). Although the average length of
follow-up was 70 weeks, the long-term DFT remained
stable up to two to three years after implantation.
DISCUSSION
The major findings of this study are that DFTs decrease
significantly over time with a dual-coil, active pectoral lead
system. The temporal decline in DFT was most marked
among patients with high DFTs ($15 J) at implantation,
which is the subgroup in which the long-term stability of
defibrillation efficacy is most important. Patients with low
DFTs (,15 J) at implantation also exhibited a significant,
albeit smaller, decline in DFT at long-term follow-up.
Although a small proportion of the patients in this study
had an increase in DFT at long-term follow-up, these
minor fluctuations were within the range expected with
repeated step-down DFT testing in individual patients (24).
Previous studies. Long-term changes in DFTs are influ-
enced by several factors, such as the lead system that is
employed and the defibrillation waveform. Long-term
DFTs are stable with epicardial lead systems, except when
patients are treated with amiodarone (25,26). In contrast,
when monophasic waveforms are used with non-
thoracotomy lead systems, a consistent long-term increase
in DFT is observed (8–12). We previously demonstrated
that biphasic waveforms prevent the long-term rise in DFT
seen with a dual-coil transvenous lead system (23); however,
other investigators have reported that up to 15% of patients
may develop a long-term rise in DFT that is large enough
to mandate device reprogramming or system revision (13).
Long-term rises in DFT are also observed when biphasic
waveforms are used with hybrid lead systems that incorpo-
rate transvenous and subcutaneous elements (14,15). The
present study is the first prospective evaluation of the
long-term stability of DFTs with an active pectoral, dual-
coil lead system. Active pectoral lead systems are currently
the most commonly used configuration because of the
simplicity of the implantation procedure and because DFTs
at implantation are lower when an active pectoral can is used
(16–18). Our findings were recently corroborated by pre-
liminary data from the larger multicenter Low Energy
Safety Study (LESS) (27). When routine ICD testing was
performed at one year after implantation in this study,
99.6% of induced ventricular fibrillation episodes were
Figure 2. Change in defibrillation thresholds (DFTs) as a function of time.
There was no relationship between temporal changes in DFT and the
timing of long-term testing (R2 5 0.001, p 5 0.79).
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successfully converted with programmed shock energies that
were 6 to 12 J greater than the DFT at implantation.
Mechanisms of action. The mechanisms responsible for
temporal changes in DFT remain poorly understood. We
previously demonstrated that when monophasic waveforms
are used with a transvenous lead system, a rise in shock
impedance is sufficient to account for the increase in
defibrillation energy at the threshold (8), assuming that
current is the major determinant of defibrillation (28,29).
However, when temporal changes in DFT with monophasic
and biphasic waveforms were compared in a single patient
cohort, biphasic DFTs were unchanged, despite a signifi-
cant increase in shock impedance (23). This suggests that
shock impedance is an important determinant of threshold
energy for monophasic, but not biphasic, waveforms. In the
present study, the long-term biphasic DFT declined signif-
icantly with an active can, dual-coil transvenous lead system.
This decrease cannot be attributed to the waveform or
changes associated with maturation of the transvenous lead,
because long-term DFTs are unchanged when this wave-
form and lead are used without an active pectoral pulse
generator (23). The stress of surgery is also unlikely to
account for the higher DFT at implantation, because there
was no significant difference between the DFT values at
implantation and before discharge. However, because the
pulse generator shell is a component of the defibrillation
system, the temporal decline in DFT may be related to
maturation of the pocket. With the dual-coil, active can
configuration, there are two pathways for current flow: from
the distal right ventricular coil to either the proximal coil or
the pectoral pulse generator. It is possible that maturation of
the pulse generator pocket results in a favorable change in
the distribution of current between these two pathways,
thereby improving defibrillation efficacy.
Clinical implications. Our findings indicate that routine
DFT testing may not be necessary for at least the first two
years after implantation with an active pectoral, dual-coil
lead system if an adequate safety margin for defibrillation is
present at the time of implantation. Relatively few patients
in this study were treated with amiodarone, which can
increase the DFT (30). This was because most of the
patients who required concomitant treatment with amioda-
rone underwent long-term DFT testing before initiation of
the drug. Accordingly, we would still recommend serial
evaluation of the DFT among patients treated with antiar-
rhythmic drugs or in the case of a changing cardiac substrate
(e.g., worsening congestive heart failure, severe left ventric-
ular dysfunction, new myocardial infarction) (31).
Study limitations. A uniform lead system and defibrilla-
tion waveform were employed in this study to avoid any
confounding influence of these factors on the results.
Consequently, our findings may not be applicable to other
defibrillation systems that employ different waveforms and
leads. Although the pectoral electrode was an emulator at
implantation and the pulse generator shell at subsequent
evaluations, a decline in DFT was also observed when the
long-term follow-up and predischarge measurements were
compared. The defibrillation step-down protocol that we
used has some limitations. The relationship between defi-
brillation success and energy is best described as a dose-
response curve (32). The use of a step-down protocol to first
failure to determine DFTs has provided a reasonable esti-
mate of the 70% defibrillation success energy (33), and it has
been shown to be reproducible (34). It is highly unlikely that
our results are attributable to spontaneous variability with
repeated measurements of the step-down DFT. With suc-
cessive DFT determinations, one would expect equal pro-
portions of patients to exhibit an increase or decrease in
DFT (24). In contrast, we observed that DFT at long-term
follow-up decreased in 50% of patients and increased in only
10% of patients. The fact that DFTs measured at implan-
tation and before discharge did not differ significantly also
suggests that the step-down DFT method was reproducible
in this patient group. This study did not consist of a
consecutive series of patients; however, our results are
unlikely to be attributable to patient selection, because the
clinical characteristics of the study patients were comparable
to those of other patients who underwent initial pectoral
ICD placement with an active pectoral, dual-coil trans-
venous lead system at our institution during this interval.
Although some of our patients underwent long-term ICD
testing as late as three to four years after ICD placement,
the majority of the long-term ICD tests were performed
within the first two years. Therefore, it is presently unclear
whether DFT testing should be performed at later intervals
(i.e., between two years after implantation and pulse gen-
erator replacement). Our results should not be extrapolated
to patients who do not have an acceptable safety margin for
defibrillation at implantation, because these patients were
excluded from our study. Finally, treatment with antiar-
rhythmic drugs can have important effects on temporal
changes in DFT (22); however, our results were unchanged
when these patients were excluded from the analysis.
Conclusions. Our results demonstrate that DFTs decline
significantly after implantation with an active pectoral,
dual-coil lead system. The magnitude of the decline was
most marked among patients with high DFTs at implan-
tation, who would have been considered to be at greatest
risk for the development of an inadequate safety margin for
defibrillation. These results indicate that routine DFT
testing may not be required during the first two years after
implantation with this lead system, in the absence of a
change in the cardiac substrate or treatment with antiar-
rhythmic drugs.
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